Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy (...)
06 / 29 / 2022
06 / 16 / 2022
05 / 31 / 2022
As Olink®-certified service Provider, Explicyte offers now high proteomic analysis capabilities for comprehensive protein biomarker discovery using Olink® Target technology.
Olink®’s Target96 biomarker panels are dedicated to many diseases and/or biological processes. You can directly download them from the form below and do not hesitate to let us know your proteomics projects!05 / 26 / 2022
Nature medicine, 2022, May 26
A. Italiano , A. Bessede, M. Pulido, E. Bompas , S. Piperno-Neumann, C. Chevreau, N. Penel, F. Bertucci, M. Toulmonde, C. Bellera, J. P. Guegan, C. Rey, C. Sautès-Fridman , A. Bougoüin, C. Cantarel, M. Kind, M. Spalato, B. Dadone-Montaudie, F. Le Loarer, J. Y. Blay and W. H. Fridman
05 / 19 / 2022
From June 3 to 7, 2022, we will be setting up our quarters in Chicago for the American Society of Clinical Oncology Annual Meeting to continue gaining the latest insights in research and clinical development in Oncology. Also, our CEO Dr. Alban Bessede will have the great opportunity to present a scientific poster highlighting our recent advances in biomarker research in Immuno-Oncology.
05 / 12 / 2022
Development and characterization of a novel anti-PD1 resistant sarcoma mouse model
Soft Tissue Sarcoma (STS) is known to be refractory to current cancer immunotherapies including the PD1 immune checkpoint inhibitor (ICI) (Toulmonde et al., 2018), thus claiming the development of novel therapeutic strategies aiming at improving the current clinical benefit.